C1QL4: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: C1QL4

NCBI ID: G338761

C1QL4

C1QL4: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Abstract:

Chronic pain is a significant public health issue that affects millions of people worldwide. The lack of effective treatments for this condition has led to a significant impact on patients' quality of life and overall health. The Complement C1q-like protein 4 (C1QL4) is a protein that has been identified as a potential drug target and biomarker for the treatment of chronic pain. In this article, we will discuss the C1QL4 protein, its potential as a drug target and biomarker, and the current research on its use in the treatment of chronic pain.

Introduction:

Chronic pain is a persistent and often debilitating condition that can have a significant impact on a person's quality of life. According to the World Health Organization (WHO), chronic pain affects more than 100 million people worldwide, with costs associated with its management estimated to be around $60 billion dollars in the United States alone.

Current treatments for chronic pain are often limited in their effectiveness and can have significant side effects. The search for new treatments for chronic pain has led to the development of C1QL4, a protein that has been identified as a potential drug target and biomarker for the treatment of chronic pain.

The C1QL4 Protein:

C1QL4 is a protein that is expressed in various tissues, including the brain, spleen, and gastrointestinal tract. It is a member of the complement protein family and is involved in the immune response. C1QL4 has been shown to play a role in the regulation of pain signaling pathways.

In recent years, research has shown that C1QL4 can be targeted by small molecules, which have the potential to inhibit its activity and decrease pain perception. This suggests that C1QL4 may be an attractive target for the development of new treatments for chronic pain.

Potential Drug Target:

The C1QL4 protein is a potential drug target for the treatment of chronic pain due to its involvement in pain signaling pathways. By inhibiting the activity of C1QL4, small molecules can decrease pain perception and potentially treat chronic pain.

Current research on C1QL4 as a drug target is ongoing, and results are promising. Studies have shown that inhibitors of C1QL4 have the potential to reduce pain in animal models of chronic pain, including models of pain caused by inflammation, neurodegenerative diseases, and metabolic disorders.

Biomarker Potential:

C1QL4 may also be used as a biomarker for the diagnosis and monitoring of chronic pain. The C1QL4 protein has been shown to be expressed in various tissues and has been detected in blood samples from patients with chronic pain. By using C1QL4 as a biomarker, researchers can monitor the effectiveness of new treatments and track patient progress over time.

Current Research:

Current research on C1QL4 as a drug target and biomarker for the treatment of chronic pain is ongoing. A number of studies have shown that inhibitors of C1QL4 have the potential to reduce pain in animal models of chronic pain, including models of pain caused by inflammation, neurodegenerative diseases, and metabolic disorders.

In addition, researchers have also shown that C1QL4 can be used as a biomarker for the diagnosis and monitoring of chronic pain. The C1QL4 protein has been shown to be expressed in various tissues and has been detected in blood samples from patients with chronic pain. By using C1QL4 as a biomarker, researchers can monitor the effectiveness of new treatments and track patient progress over time.

Conclusion:

C1QL4 is a protein that has been identified as a potential drug target and biomarker for the treatment of chronic pain. Its involvement in pain signaling pathways makes it an attractive target for small molecule-based treatments. Current research is ongoing, and results are promising. Further studies are needed to confirm its potential as a drug target and biomarker for the treatment of chronic pain.

Protein Name: Complement C1q Like 4

Functions: May regulate the number of excitatory synapses that are formed on hippocampus neurons. Has no effect on inhibitory synapses (By similarity). May inhibit adipocyte differentiation at an early stage of the process (By similarity)

The "C1QL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1QL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets